Results 71 to 80 of about 20,923 (159)

Role of Empagliflozin in heart failure with severe aortic stenosis before valve replacement: EASTER-HF study

Indian Heart Journal
We evaluated empagliflozin in severe DAS patients with HF before AVR. HF patients with LVEF 30–80 % and NYHA functional class II-IV symptoms got empagliflozin 10 mg or not within 6 months before AVR, along with SOC. Adding empagliflozin to the SOC before
Pankaj Jariwala, Gururaj Pramod Kulkarni, Arshad Punjani, Harikishan Boorugu, Dilip Gude   +4 more
doaj   +1 more source

5.1 EFFECTS OF THE SGLT-2 INHIBITOR EMPAGLIFLOZIN ON VASCULAR FUNCTION AND CENTRAL HEMODYNAMICS IN PATIENTS WITH TYPE 2 DIABETES

Artery Research, 2017
Background: The selective sodium-glucose cotransporter 2 (SGLT-2) inhibitor empagliflozin leads to improved cardiovascular, renal and heart failure outcome in secondary prevention.
Christian Ott, Kristina Striepe, Agnes Jumar, Marina Karg, Markus Schneider, Dennis Kannenkeril, Roland Schmieder   +6 more
doaj   +1 more source

Effect of Semaglutide and Empagliflozin on Pulmonary Structure and Proteomics in Obese Mice

Yu Yang,1,2 Xiaoyu Pan,1,3 Shuchun Chen1,3 1Department of Internal Medicine, Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of ...
Pan X, Yang Y, Chen S
core  

Empagliflozin improves renal injury of diabetic nephropathy complicated with hyperuricemia through AMPK by promoting autophagy and inhibiting apoptosis

Saudi Pharmaceutical Journal
Objective This study aimed to investigate how empagliflozin alleviates renal injury in diabetic nephropathy with hyperuricemia by activating AMPK and regulating autophagy and apoptosis.
Zhiqin Zhang, Yanmei Xu, Chuanwen Xu, Qi Gao, Xiaoyan Wu, Ting Wu   +5 more
doaj   +1 more source

Comparison of the effects of empagliflozin and sitagliptin, as an add-on to metformin, on cardio-metabolic and glycemic parameters of patients with type 2 diabetes mellitus: a randomized, double-blind clinical trial

BMC Research Notes
Objective To evaluate the effects of empagliflozin, sitagliptin, and metformin on the glycemic indices and cardiometabolic control of patients with type 2 diabetes mellitus (T2DM). Results The significant changes in FBS from baseline to week 12 were − 23.
Naimeh Mesri Alamdari, Maryam Barghaman, Neda Roshanravan, Majid Mobasseri, Helda Tutunchi, Amir Baharami, Akbar Aliasgarzadeh, Vahideh Sadra   +7 more
doaj   +1 more source

Sodium Glucose Transporter 2 Inhibitor Protects Against Heart Failure With Preserved Ejection Fraction: Preclinical “2‐Hit” Model Reveals Autophagy Enhancement Via AMP‐Activated Protein Kinase/Mammalian Target of Rapamycin Complex 1 Pathway

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Heart failure with preserved ejection fraction (HFpEF) is a multifaceted syndrome with high morbidity and mortality. Empagliflozin, an SGLT2 (sodium–glucose cotransporter 2) inhibitor, reduces adverse events in patients with HFpEF regardless ...
Xinyu Hu, Dan Li, Weijie Chen, Hongyu Kuang, Dan Yang, Zhiyan Gong, Yuxiang Long, Guangliang Liu, Kai Wang, Mengshi Xia, Yanping Xu, Yuehui Yin   +11 more
doaj   +1 more source

Empagliflozin and Dapagliflozin Outcomes in Heart Failure.

IMPORTANCE: Sodium-glucose cotransporter-2 inhibitors have emerged as important therapeutic options for heart failure (HF). However, their comparative clinical effectiveness remains uncertain.
Kim, H, Aung, N, Kim, S, Ahn, H-S, Shin, D-H, Lee, D, Bu, S, Chung, D, Jung, M-H, Cho, JS, Yi, J-E, Hwang, Y-M   +11 more
core   +1 more source

Empagliflozin in De Novo vs Acute Decompensated Chronic Heart Failure

International audienceBACKGROUND In EMPULSE (A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure), the sodium-glucose cotransporter 2 inhibitor empagliflozin improved clinical outcomes in patients ...
Ferreira, Joao Pedro, Teerlink, John, R, Angermann, Christiane, E, Kraus, Bettina, J, Tromp, Jasper, Gerhardt, Teresa, Ponikowski, Piotr, Nassif, Michael, E, Voors, Adriaan, A, Blatchford, Jonathan, P, Kosiborod, Mikhail, Psotka, Mitchell, A, Biegus, Jan, Collins, Sean, P   +13 more
core   +1 more source

Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet

Diabetes, Metabolic Syndrome and Obesity, 2014
Steven P Vickers,1 Sharon C Cheetham,1 Katie R Headland,1 Keith Dickinson,1 Rolf Grempler,2 Eric Mayoux,2 Michael Mark,2 Thomas Klein2 1RenaSci, BioCity Nottingham, Nottingham, UK; 2Boehringer Ingelheim Pharma, Biberach an der Riss, Germany Abstract ...
Vickers SP, Cheetham SC, Headl, KR, Dickinson K, Grempler R, Mayoux E, Mark M, Klein T   +8 more
doaj  

Effects of SGLT-2 Inhibitors on Plasma Concentrations and Renal Clearance of the Risk Marker Trimethylamine-N-Oxide in Patients With Type-2 Diabetes. [PDF]

Endocrinol Diabetes Metab
Zimmer KB, Gessner A, Kannenkeril D, Bosch A, Ströbel A, Schmieder RE, Maas R.   +6 more
europepmc   +1 more source